GRR-VHIR has enlarged its own highly-equipped installations (200m2) in VHIR & PCB. The new model of organization includes Basic, Translational & Clinical Research, structured in 3 areas: IMID-Biobank-ISO9001-2015 certified continues to collect cross-sectional and longitudinal patient samples from RA, IBD, PsO, PsA, AD, SSj, and SLE, and healthy Control subjects, generating >8M vials of >17,000 biological samples, and>120,000 biological products (plasma, serum, urine, buffy coats, PBMCs). Research: development of the rheumatology clinical and translational research lines, including SLE and APS, CFS, FM, rheumaticdiseases in pediatric age, musculoskeletal US, inflammatory myopathies, bonemetabolism, pregnancy in rheumatic diseases, SpA & PsA, oncoimmunology & Interstitial pulmonary disease. Clinical Trials Unit: Phases I-IV, & Independent Clinical Research. Strategic actions: Reorganization of the research area; Incorporation of new highly qualified research staff; Creation of CT Unit.
Group Leader
Antonio Julia Cano, Sara Marsal
Principal Investigator (PI)
José Alegre Martín, Josefina Cortés Hernández, Juan José de Agustín de Oro, María América Lopez Lasanta, Ernesto Trallero Araguás, Jesús Castro Marrero, Mayte Serrat López, Cristina Solé Marcé, Raul Tortosa Méndez
Researchers
Mireia Barceló Brú, Adrià Aterido Ballonga, M Alba Erra Duran, Jordi Francesc Lladós Segura, Andrea Pluma Sanjurjo, Núria Palau Balañá, Ramon Sanmartín Sentañes
PhD Students
Estefanía Moreno Ruzafa, Miriam Almirall Bernabé, Helena Borrell Paños, María Pascual Pastor, Gustavo Adolfo Áñez Sturchio, Irene Bonafonte Pardàs, Sandra Domingo Bover, Judith Fernández Quirós, Mireia López Corbeto, Xabier Michelena Vegas, Laia Martínez Mitjana, Rafael Touriño García, Luís Coronel Tarancón, Hugo Fernando Ávalos Bogado, Sebastián Sandoval Moreno, Esther Espartal López, Alejandro Gómez Gómez
Lab Technicians
Alba Frías García, Ares Sellés Rius, Anna Tirado
Nursing and Technical Staff
Elena Granell Pallares, Raquel María Lastra Borras, Marta Musté Díaz, Montserrat Sender Beleta, Anna Roig Izquierdo
31
PUBLICATIONS
278
IMPACT FACTOR
8.96
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Sara Marsal, Héctor Corominas, Juan José de Agustín, Carolina Pérez-García, María López-Lasanta, Helena Borrell, Delia Reina, Raimón Sanmartí, Javier Narváez, Clara Franco-Jarava, Charles Peterfy, José Antonio Narváez, Vivek Sharma, Konstantinos Alataris, Mark C Genovese, Matthew C Baker
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study
The Lancet Rheumatology, Volume 3, Issue 4, 2021, Pages e262-e269
DOI: doi.org/10.1016/S2665-9913(20)30425-2
IF: 8.136
Trallero-Araguás E, Gil-Vila A, Martínez-Gómez X, Pinal-Fernández I, Alvarado-Cardenas M, Simó-Perdigó M, Selva-O'Callaghan A
Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center
Semin Arthritis Rheum. 2021 Dec 31;53:151940. doi: 10.1016/j.semarthrit.2021.12.008. Epub ahead of print
DOI: doi.org/10.1038/s41598-021-90797-0
IF: 3.998
Julià, A., Bonafonte-Pardàs, I., Gómez, A
Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19
Sci Rep 11, 11462 (2021)
DOI: doi.org/10.1038/s41598-021-90797-0
IF: 3.998
Joan Carles Domingo, Begoña Cordobilla, Roser Ferrer, Marina Giralt, José Alegre-Martín, and Jesús Castro-Marrero
Are Circulating Fibroblast Growth Factor 21 and N-Terminal Prohormone of Brain Natriuretic Peptide Promising Novel Biomarkers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?
Antioxidants & Redox Signaling 2021 34:18, 1420-1427
DOI: NA
IF: 7.04
Domingo S, Solé C, Moliné T, Ferrer B, Cortés-Hernández J
Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways
Biomedicines. 2021 Dec 7;9(12):1857. doi: 10.3390/biomedicines9121857
DOI: NA
IF: 6.08
Decision on Optimal Combinatorial therapies in IMIDs using systems approaches. DocTIS
Principal Investigator: Sara Marsal
Agency: H2020-SCH1-BHC-02-2019. European Union H2020
Funding: 6.2 M€
Period: 2020-25
Anti-TNF therapy patient stratification in rheumatoid arthritis. Synovial membrane spatial transcriptome characterization of response and association to protein biomarkers in plasma
Principal Investigator: Antonio Julià
Agency: PI21/01185. ISCIII
Funding: 196,020€
Period: 2021
Terapia génica con miRNAs de interferencia como nueva alternativa de tratamiento en el lupus cutáneo discoide (LED)
Principal Investigator: Cristina Solé Marcé
Agency: PI21/01869. ISCIII
Funding: 99,099€
Period: 2021
Análisis multiómico unicelular para agrupar pacientes con nefritis lúpica según la respuesta clínica: hacia la medicina de precisión en nefritis lúpica
Principal Investigator: Josefina Cortés-Hernández
Agency: PI21/00287 ISCIII
Funding: 141,570€
Period: 2021
Study of Functional Brain Magnetic Resonance in patients with Psoriasis Arthritis and Psoriasis treated with targeted therapies. BREFPOD
Principal Investigator: Sara Marsal
Agency: ASPIRE grant – Pfizer
Funding: 145,200 €
Period: 2021-23
Therapy selection for psoriasis and psoriatic arthritis
Priority Number: PCT/IB2015/056212
Priority Date: 2017-06-21
Applicants: Application filed by Hospital Clinic de Barcelona, Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR, Fundacio Institut dInvestigació en Ciencies de la Salut Germans Trias I Pujol IGTP
Methods of predicting response to treatment with anti-TNF alpha biological inhibitors
Priority Number: PCT/IB2015/055840
Priority Date: 2017-01-31
Applicants: Application filed by Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Method for predicting the clinical response to treatment with anti-inflammatory agents
Priority Number: EP14179452.9A
Priority Date: 2015-07-31
Applicants: Application filed by Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Risk locus for psoriatic arthritis
Priority Number: US62/151,952
Priority Date: 2015-04-23
Applicants: Application filed by Fundació Hospital Universitari Vall D’Hebron-Institut De Recerca, Hospital Clinic De Barcelona, Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol
Method to predict the lack of response to anti-tnf alpha therapies
Priority Number: PCT/EP2014/066604
Priority Date: 2014-08-01
Applicants: Application filed by Fundació Hospital Universitari Vall D'hebron - Institut De Recerca, Hospital Clínic De Barcelona
